"Long-term use of Rem's sleep behavioral disorder does not affect cognitive function"
Sep 01, 2024
Rem sleep behavior disorder is a disease that shows violent behavior such as screaming or swinging limbs while sleeping, and it is normal for muscles to be paralyzed and unable to move in REM sleep, but patients with REM sleep behavior disorder are relieved of muscle paralysis and move their dream behavior.
It is known that most of the treatment improves symptoms by taking a treatment containing clonazepam, a type of benzodiazepine drug. However, symptoms reappear as soon as you stop taking them, and it is common to take treatment for a long time.
However, REM sleep behavioral disorder is at high risk of developing into neurodegenerative diseases such as Parkinson's disease and Louisocere dementia, and some have reported that long-term use of benzodiazepine drugs, including clonazepam, can reduce cognitive function, raising concerns among patients with REM sleep behavioral disorder, which is inevitable to take long-term use of clonazepam.
Meanwhile, a research team led by Professor Yoon In-young of the Department of Mental Health at Seoul National University Bundang Hospital (first author Lee Min-ji of the Department of Mental Health at Soonchunhyang University Seoul Hospital) has announced a study that long-term use of clonazepam, a treatment for idiopathic REM sleep behavioral disorder, is not related to cognitive decline.
The research team followed 101 patients diagnosed with idiopathic REM sleep behavior disorder at the sleep center of Seoul National University Bundang Hospital for an average of 7 years.
As a result, memory and performance ability to construct cognitive function were slightly reduced in patients with high cumulative clonazepam doses. Accordingly, the research team analyzed the effects of risk factors such as ▲ body mass index including cumulative clonazepam doses ▲ smoking status ▲ alcohol intake ▲ high blood pressure ▲ base (before treatment for REM sleep behavior disorder) on cognitive function.
According to the research team, only the underlying cognitive function of patients with REM sleep behavioral disorder was related to cognitive decline in the future, and the cumulative dose of clonazepam did not show any significant correlation in all areas of cognitive function, including memory, space-time function, performance ability, and overall cognition. Through this, it was confirmed that the underlying cognitive function acts as a more important factor in cognitive decline than the cumulative dose of clonazepam.
Professor Yoon In-young said, "This is the first study to investigate the correlation between the cumulative dose of clonazepam and cognitive decline in patients with idiopathic REM sleep behavioral disorder. As it has been found that long-term use of REM sleep behavioral disorder does not have a significant impact on cognitive decline, if REM sleep behavioral disorder is suspected, good treatment results will be obtained if it is diagnosed early and taken steadily.".
Meanwhile, the results of this study were recently published in the SCI-level international journal 『Journal of Clinical Sleep Medicine』.
Reporter Jang Jong-ho bellho@sportschosun.com
It is known that most of the treatment improves symptoms by taking a treatment containing clonazepam, a type of benzodiazepine drug. However, symptoms reappear as soon as you stop taking them, and it is common to take treatment for a long time.
However, REM sleep behavioral disorder is at high risk of developing into neurodegenerative diseases such as Parkinson's disease and Louisocere dementia, and some have reported that long-term use of benzodiazepine drugs, including clonazepam, can reduce cognitive function, raising concerns among patients with REM sleep behavioral disorder, which is inevitable to take long-term use of clonazepam.
Meanwhile, a research team led by Professor Yoon In-young of the Department of Mental Health at Seoul National University Bundang Hospital (first author Lee Min-ji of the Department of Mental Health at Soonchunhyang University Seoul Hospital) has announced a study that long-term use of clonazepam, a treatment for idiopathic REM sleep behavioral disorder, is not related to cognitive decline.
The research team followed 101 patients diagnosed with idiopathic REM sleep behavior disorder at the sleep center of Seoul National University Bundang Hospital for an average of 7 years.
As a result, memory and performance ability to construct cognitive function were slightly reduced in patients with high cumulative clonazepam doses. Accordingly, the research team analyzed the effects of risk factors such as ▲ body mass index including cumulative clonazepam doses ▲ smoking status ▲ alcohol intake ▲ high blood pressure ▲ base (before treatment for REM sleep behavior disorder) on cognitive function.
According to the research team, only the underlying cognitive function of patients with REM sleep behavioral disorder was related to cognitive decline in the future, and the cumulative dose of clonazepam did not show any significant correlation in all areas of cognitive function, including memory, space-time function, performance ability, and overall cognition. Through this, it was confirmed that the underlying cognitive function acts as a more important factor in cognitive decline than the cumulative dose of clonazepam.
Professor Yoon In-young said, "This is the first study to investigate the correlation between the cumulative dose of clonazepam and cognitive decline in patients with idiopathic REM sleep behavioral disorder. As it has been found that long-term use of REM sleep behavioral disorder does not have a significant impact on cognitive decline, if REM sleep behavioral disorder is suspected, good treatment results will be obtained if it is diagnosed early and taken steadily.".
Meanwhile, the results of this study were recently published in the SCI-level international journal 『Journal of Clinical Sleep Medicine』.
Reporter Jang Jong-ho bellho@sportschosun.com
|
bellho@sportschosun.com
